Nimotuzumab Combined With VMAT in Elderly Patients With Nasopharyngeal Carcinoma

NCT03915132 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

47

Enrollment

OTHER

Sponsor class

Conditions

Nasopharyngeal Carcinoma

Interventions

DRUG: Nimotuzumab
RADIATION: VMAT

Sponsor

Chinese Academy of Medical Sciences